

Table of Contents

CHAPTER 1	1
Introduction and review of literature on cross-talk between autophagy and apoptosis	1
Abstract	1
1.1. Introduction to Autophagy and Apoptosis	2
1.2. Autophagy promotes cellular survival in normal growth conditions	6
1.2.1. Roles of autophagy in whole body metabolism	6
1.2.2. Roles of autophagy in the development and differentiation processes	11
1.3. Autophagy in cancer	16
1.3.1. Autophagy in stress (below threshold value) behaves as tumor suppressor	16
1.3.2. Autophagy in prolonged stress behaves as tumor promoter	20
1.3.3. Autophagy in stress (beyond threshold value), switched to apoptotic cell death	25
1.4. Autophagy in other pathophysiologies	33
1.4.1. Autophagy in neural disorders	33
1.4.2. Autophagy in cardiac disorders	35
1.4.3. Autophagy in inflammatory diseases	39
1.4.4. Autophagy in viral diseases	40
1.5. Scope and objectives of the current study	41
CHAPTER 2	
Repurposing of FDA-approved drugs as autophagy inhibitors in tumor cells	43
Abstract	43
2.1. Introduction	44
2.2. Methodology	46
2.2.1. Retrieval and preparation of protein	46

2.2.2. Retrieval and preparation of ligands	47
2.2.3. Assessment of druglikeness of the ligands	48
2.3.4. Molecular Dynamics (MD) simulation study	48
2.2.5. MM/PBSA for free energy calculations	50
2.2.6. Analysis and visualization	52
2.3. Results and Discussion	52
2.3.1. Molecular Docking	52
2.3.2. Assessment of druglikeness of ligand	59
2.3.3. MD Simulations analysis	61
2.3.4. Analysis of results of MM/PBSA method after MD simulation	66
2.4. Conclusion	69
CHAPTER 3	70
Virtual screening and repurposing of FDA-approved drugs from zinc database to identify potential autophagy inhibitors exploiting ATG4A cysteine peptidase as a target: potential as novel anti-cancer molecule	70
Abstract	70
3.1. Introduction	71
3.2. Methodology	73
3.2.1. Preparation of target protein	73
3.2.2. Drug molecule screening through molecular docking	74
3.2.3. ADME analysis	75
3.2.4. Molecular Dynamics (MD) Simulation study	75
3.2.5. Calculations of average binding energy through MM/PBSA method	77
3.2.6. Analysis and visualization	77
3.3. Results and Discussion	78
3.3.1. Molecular Docking	78
3.3.2. Assessment of Druglikeness	88
3.3.3. MD Simulation analysis	89
3.3.4. Analysis of average binding energy through MM/PBSA method	95

3.4. Conclusion	99
CHAPTER 4	100
<i>In vitro</i> investigations on effect of Ponatinib on interplay between autophagy and apoptosis focusing upon Beclin-1 and Bcl-2 interaction	100
Abstract	100
4.1. Introduction to the interplay between autophagy and apoptosis	101
4.2. Materials and Methods	104
4.2.1. Reagents and antibodies	104
4.2.2. Cell line and the culture condition	104
4.2.3. Metabolic activity assay	105
4.2.4. RNA extraction and cDNA synthesis	106
4.2.5. Real-time PCR (qPCR) analysis	106
4.2.6. Western blot assay	107
4.2.7. Immunofluorescence assay	108
4.2.8. Apoptosis assay	110
4.2.9. Statistical analysis	110
4.3. Results and Discussion	111
4.3.1. Ponatinib inhibited the proliferation of human breast cancer cells MCF-7	111
4.3.2. Ponatinib induces the autophagy initially, further inhibits the autophagic flux, and subsequently triggers apoptosis in MCF-7 cells	113
4.3.3. Rapamycin, a positive regulator of autophagy, exerts a synergistic effect on Ponatinib and triggers the inhibition in the autophagic flux and, subsequently, the apoptosis in MCF-7 cells.	130
4.3.4 3-Methyladenine, a negative regulator of autophagy, helps identify the cell death is autophagy-mediated in MCF-7 cells.	138
4.3.5 Doxorubicin, a positive regulator of apoptosis, helps identify that the cell death is not an independent apoptosis	145
4.3.6 SP600125, a regulator that drives the cell's fate from autophagy to apoptosis, does not show a synergistic effect on Ponatinib	151
4.3.7 Ponatinib sensitizes the MCF-7 cells to autophagy-mediated cell death and shows a pronounced effect with pharmacological modulators of autophagy and apoptosis.	158

4.4. Conclusion	167
CHAPTER 5	169
Conclusion and Future Scope	169- 176
References	177- 188
APPENDIX A	189
List of Publications from Thesis Work	189
APPENDIX B	190
Conferences and Workshops	190